Future developments in the treatment of lung cancer.
Lung cancer is the most frequent cause of cancer deaths in the western world. Despite some improvements in treatment results, especially by the use of combined treatment modalities, the overall prognosis is still very poor, and less than 15% of the patients survive 5-year after primary diagnosis. Through rapid developments in biotechnology and increased knowledge about important signaling pathways leading to cell proliferation, apoptosis, angiogenesis and metastases, new treatment possibilities with specific targeted therapies have emerged for chemoprevention and treatment of lung cancer. Together with developments of new technology available for early diagnosis new paradigms for management of lung cancer are under development with great promises for improvement of the overall prognosis.
Hirsch
Fred R
FR
Department of Medical Oncology/Pathology, University of Colorado, Cancer Center, B 188, 4200 East Ninth Avenue, Denver, CO 80262, USA. fred.hirsch@uchsc.edu
Fischer
Jürgen R
JR
Niklinski
Jacek
J
Zöchbaüer-Müller
Sabine
S
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D005544:Forecasting; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D000068878:Trastuzumab
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011505:Protein-Tyrosine Kinases; D000068878:Trastuzumab